Molluscum Contagiosum Treatment Therapeutics

1. Zelsuvmi patent expiration

Treatment: Method of administering a nitric oxide releasing active pharmaceutical ingredient to treat and/or prevent viral infection; Method of treating and/or preventing viral infection using a nitric oxide rel...

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8956658 LNHC Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
May, 2026

(4 months from now)

US8282967 LNHC Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
May, 2026

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11723858 LNHC Topical antiviral compositions, delivery systems, and methods of using the same
Jul, 2035

(9 years from now)

US11040006 LNHC Topical antiviral compositions, delivery systems, and methods of using the same
Jul, 2035

(9 years from now)

US10736839 LNHC Topical antiviral compositions, delivery systems, and methods of using the same
Jul, 2035

(9 years from now)

US10322081 LNHC Topical antiviral compositions and methods of using the same
Jul, 2035

(9 years from now)

US10258564 LNHC Topical compositions and methods of using the same
Nov, 2034

(8 years from now)

US9855211 LNHC Topical compositions and methods of using the same
Feb, 2034

(8 years from now)

US9737561 LNHC Topical gels and methods of using the same
Aug, 2030

(4 years from now)

US9289442 LNHC Topical compositions
Jul, 2032

(6 years from now)

US11285098 LNHC Topical compositions and methods of using the same
Feb, 2034

(8 years from now)

US10376538 LNHC Topical gels and methods of using the same
Aug, 2030

(4 years from now)

US9526738 LNHC Topical gels and methods of using the same
Sep, 2031

(5 years from now)

US10265334 LNHC Anhydrous compositions
Jul, 2032

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 05, 2029

Drugs and Companies using BERDAZIMER SODIUM ingredient

NCE-1 date: 06 January, 2028

Market Authorisation Date: 05 January, 2024

Dosage: GEL

More Information on Dosage

ZELSUVMI family patents

Family Patents